Beste apotheek van Nederland

Treatment
Study ED Etiology Group
% (n/N)
mild-tomoderate
ED
(Study a)
Padma-
Nathan 2003
6 weeks
Patients with
severe ED
(study b)
NR
92.0 (24/26)
200 µg
71.7 (66/92)
All doses
58.8 (20/34)
100 µg
75.9 (22/29)
200 µg
82.7 (24/29)
300 µg
Control
Group
% (n/N)
Relative Risk
[95% CI]
54.8 (17/31) 1.68
[1.20–2.36]
25.7 (9/35) 2.79
[1.57–4.97]
25.7 (9/35) 2.29
[1.22–4.29]
25.7 (9/35) 2.95
[1.62–5.37]
25.7 (9/35) 3.22
[1.79–5.79]
Aminophylline + Isosorbide dinitrate + Co-dergocrine vs. Placebo,
Gomaa 1996 Physiologic: 52.3%
Psychogenic: 25%
Mixed: 22.2%
Le Roux 1999 Physiologic: 28.6%
Psychogenic: 71.4%
Minoxidil vs. Nitroglycerin
58.3 (21/36) 8.3 (3/36) 7.00
[2.29–21.41]
3.9 (3/77
applications,
8 patients)
5.3 (4/76
applications,
8 patients)
0.74
[0.17–3.20]
Cavallini 1994 Physiologic: 100% 44.0 (51/116) 20.7 (24/116) 2.13
[1.41–3.21]
Minoxidil vs. Placebo
Cavallini 1994 Physiologic: 100% 44.0 (51/116) 1.7 (2/116) 25.5
[6.36–102.29]
Nitroglycerine plasters vs. Placebo plasters
Gramkow Physiologic: 27.8%
1999 Psychogenic: 66.7%
Mixed: 5.6%
16.7 (3/18) 11.1 (2/18)
1.50
[0.28–7.93]
Topical sildenafil + Oral placebo vs. Oral sildenafil + Topical placebo,
Yonessi 2005 Physiologic: 41.3% 12.5 (5/40) 70.0 (28/40) 0.18
Psychogenic: 58.8%
[0.08–0.42]
* Defined as full erection, erections sufficient for intercourse, improved erections based on Global Assessment
Questionnaire, or RigiScan assessment ≥ 60% rigidity (“good to excellent effect”)
** Intention-to-treat population, defined as patients receiving ≥ one dose of study medication and ≥ one post-baseline
efficacy evaluation. Of a total of 1732 patients, 83 patients (4.8%) were not evaluated
† Includes only patients from the cohort for the primary efficacy endpoint analysis, defined as (a) used ≥ three doses of
study medication in conjunction with attempts at sexual intercourse between visits 2 and 4, (b) reported both baseline
and end of treatment efficacy data (International Index of Erectile Function (IIEF), (c) reported a baseline score for the
IIEF EF domain of ≤ 21, and (d) tolerated the test dose at visit 2 †† Based on a difficulties in maintaining an erection
during intercourse scale, scored from 1 (always) to 6 (never). A score of 3 indicates difficulties 50% of the time.
159